Company
Translating immunology into therapeutic possibility.
Dys-Immune Therapeutics is a French biotechnology company developing immunotherapies that target dysregulated cytokine networks.
Our mission
A more functional immune equilibrium.
We seek to translate decades of research in immunology, HIV and immune regulation into new therapeutic approaches for severe chronic diseases.
Our initial focus is modulation of interferon-α, a key mediator of antiviral defense whose persistent activation may contribute to immune dysfunction in chronic disease.
years of scientific research
proprietary platform focus
European biotechnology company
lead therapeutic area
Scientific heritage
Four decades of research into immune control
The company’s scientific rationale builds on work led by Professor Daniel Zagury across immunology, HIV and immune regulation.
1980s–2000s
Long-term investigation of antiviral immunity and immune regulation.
2017–2024
Independent and collaborative studies deepen evidence around type-I interferon signaling.
Today
A focused development program translates this rationale into the investigational Vaxiferon® concept.
Peer-reviewed work supporting this scientific foundation is listed in full on the publications page.
View publications